Regeneron Pharmaceuticals Company Profile (NASDAQ:REGN)

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals logoRegeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company's segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. It commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases. Its marketed products include EYLEA (aflibercept) injection, Praluent (alirocumab) Injection and ARCALYST (rilonacept) injection for subcutaneous use. Its other products include Sarilumab (REGN88), Dupilumab (REGN668), REGN2222, Fasinumab (REGN475), REGN2810, REGN2176-3, Evinacumab (REGN1500) and REGN1908-1909.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: REGN
  • CUSIP: 75886F10
Key Metrics:
  • Previous Close: $371.61
  • 50 Day Moving Average: $363.10
  • 200 Day Moving Average: $385.02
  • 52-Week Range: $325.35 - $452.96
  • Trailing P/E Ratio: 48.27
  • Foreward P/E Ratio: 23.67
  • P/E Growth: 1.53
  • Market Cap: $39.19B
  • Outstanding Shares: 105,461,000
  • Beta: 1.44
Profitability:
  • Net Margins: 18.10%
  • Return on Equity: 22.51%
  • Return on Assets: 14.58%
Debt:
  • Debt-to-Equity Ratio: 0.08%
  • Current Ratio: 2.56%
  • Quick Ratio: 2.24%
Additional Links:
Companies Related to Regeneron Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) (?)
Ratings Breakdown: 12 Hold Ratings, 12 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $449.52 (20.97% upside)

Analysts' Ratings History for Regeneron Pharmaceuticals (NASDAQ:REGN)
Show:
DateFirmActionRatingPrice TargetDetails
2/16/2017Goldman Sachs Group, Inc. (The)DowngradeBuy -> NeutralView Rating Details
2/16/2017Sanford C. BernsteinReiterated RatingOutperform$420.00 -> $410.00View Rating Details
2/13/2017Piper Jaffray CompaniesUpgradeNeutral -> Overweight$359.87 -> $446.00View Rating Details
2/11/2017Leerink SwannSet Price TargetBuy$448.00View Rating Details
2/10/2017Canaccord GenuityReiterated RatingHold$450.00View Rating Details
2/10/2017Morgan StanleyLower Price TargetEqual Weight$370.00 -> $367.00View Rating Details
2/10/2017Citigroup Inc.Reiterated RatingBuy$420.00View Rating Details
2/10/2017Credit Suisse GroupReiterated RatingBuy$485.00View Rating Details
2/9/2017Cowen and CompanySet Price TargetHold$380.00View Rating Details
1/22/2017J P Morgan Chase & CoSet Price TargetHold$440.00View Rating Details
1/10/2017Wells Fargo & CompanyReiterated RatingMarket PerformView Rating Details
1/8/2017Evercore ISISet Price TargetHold$421.00View Rating Details
1/8/2017Robert W. BairdReiterated RatingNeutral$379.00 -> $369.00View Rating Details
1/8/2017BTIG ResearchReiterated RatingBuy$460.00View Rating Details
1/6/2017RBC Capital MarketsReiterated RatingOutperform$626.00 -> $598.00View Rating Details
1/6/2017Royal Bank Of CanadaLower Price TargetOutperform$626.00 -> $598.00View Rating Details
1/6/2017Chardan CapitalLower Price TargetNeutral$350.00 -> $345.00View Rating Details
12/28/2016ArgusReiterated RatingBuy$450.00View Rating Details
12/20/2016BMO Capital MarketsInitiated CoverageMarket Perform$419.00View Rating Details
11/17/2016Jefferies Group LLCReiterated RatingHold$394.00View Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$520.00View Rating Details
8/5/2016Brean CapitalReiterated RatingBuy$489.00View Rating Details
3/17/2016SunTrust Banks, Inc.Lower Price TargetNeutral$450.00 -> $410.00View Rating Details
3/15/2016GabelliInitiated CoverageBuy$574.00View Rating Details
2/11/2016Bank of America CorpReiterated RatingBuy$649.00 -> $525.00View Rating Details
2/10/2016Barclays PLCLower Price TargetEqual Weight$610.00 -> $425.00View Rating Details
8/31/2015Raymond James Financial, Inc.Initiated CoverageOutperform$615.00View Rating Details
8/4/2015Deutsche Bank AGReiterated RatingBuy$650.00 -> $720.00View Rating Details
7/22/2015Northland SecuritiesInitiated CoverageMarket Perform$560.00View Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for Regeneron Pharmaceuticals (NASDAQ:REGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2017        
2/9/2017Q4 2016$3.03$3.04$1.30 billion$1.23 billionViewListenView Earnings Details
11/4/2016Q316$2.73$3.13$1.29 billion$1.22 billionViewN/AView Earnings Details
8/4/2016Q216$2.65$2.82$1.24 billion$1.21 billionViewN/AView Earnings Details
5/5/2016Q116$2.58$2.57$1.18 billion$1.20 billionViewN/AView Earnings Details
2/9/2016Q415$3.40$2.83$1.17 billion$1.10 billionViewListenView Earnings Details
11/4/2015Q315$2.62$3.47$1.05 billion$1.14 billionViewListenView Earnings Details
8/4/2015Q215$2.77$2.89$887.03 million$999.00 millionViewListenView Earnings Details
5/7/2015Q115$2.50$2.88$820.30 million$870.00 millionViewN/AView Earnings Details
2/10/2015Q414$2.78$2.79$775.42 million$802.00 millionViewN/AView Earnings Details
11/4/2014Q314$2.57$2.52$733.04 million$726.00 millionViewN/AView Earnings Details
8/5/2014Q214$2.30$2.47$647.99 million$666.00 millionViewN/AView Earnings Details
5/8/2014Q114$0.94$0.58$609.04 million$626.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.97$2.24$579.17 million$610.00 millionViewN/AView Earnings Details
11/5/2013Q313$0.92$2.40$501.93 million$597.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.92$1.73$470.63 million$458.00 millionViewN/AView Earnings Details
5/3/2013Q1 2013$1.46$1.78$424.26 million$440.00 millionViewN/AView Earnings Details
2/14/2013Q4 2012$1.11$1.47$392.64 million$415.00 millionViewN/AView Earnings Details
10/24/2012$1.14$1.89ViewN/AView Earnings Details
7/25/2012$0.45$0.90ViewN/AView Earnings Details
4/26/2012($0.33)$0.37ViewN/AView Earnings Details
2/13/2012($0.60)($0.37)ViewN/AView Earnings Details
7/28/2011($0.40)($0.69)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Regeneron Pharmaceuticals (NASDAQ:REGN)
Current Year EPS Consensus Estimate: $13.02 EPS
Next Year EPS Consensus Estimate: $15.70 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$1.47$2.49$1.98
Q2 20161$1.62$1.62$1.62
Q3 20161$1.69$1.69$1.69
Q4 20162$1.77$2.79$2.28
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Regeneron Pharmaceuticals (NASDAQ:REGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Regeneron Pharmaceuticals (NASDAQ:REGN)
Insider Ownership Percentage: 10.40%
Institutional Ownership Percentage: 68.83%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/11/2017SanofiMajor ShareholderBuy87,298$369.71$32,274,943.58View SEC Filing  
12/12/2016Charles A BakerDirectorSell3,000$392.02$1,176,060.00View SEC Filing  
11/15/2016Arthur F RyanDirectorSell2,000$429.34$858,680.00View SEC Filing  
11/14/2016Joseph L GoldsteinDirectorSell2,125$450.00$956,250.00View SEC Filing  
7/29/2016Joseph L GoldsteinDirectorSell2,125$425.00$903,125.00View SEC Filing  
6/14/2016SanofiMajor ShareholderBuy64,731$363.86$23,553,021.66View SEC Filing  
5/24/2016Arthur F RyanDirectorSell1,000$396.64$396,640.00View SEC Filing  
5/18/2016Plew Daniel P VanEVPSell4,413$385.77$1,702,403.01View SEC Filing  
4/6/2016Joseph L GoldsteinDirectorSell2,000$425.00$850,000.00View SEC Filing  
3/21/2016Joseph L GoldsteinDirectorSell2,000$375.00$750,000.00View SEC Filing  
2/17/2016SanofiMajor ShareholderBuy161,157$392.46$63,247,676.22View SEC Filing  
1/12/2016SanofiMajor ShareholderBuy83,938$465.04$39,034,527.52View SEC Filing  
12/29/2015Douglas S. MccorkleVPSell3,954$552.08$2,182,924.32View SEC Filing  
12/10/2015Michael S. BrownDirectorSell3,000$546.45$1,639,350.00View SEC Filing  
12/2/2015George YancopoulosinsiderSell43,348$549.03$23,799,352.44View SEC Filing  
11/18/2015P Roy VagelosChairmanSell17,240$587.90$10,135,396.00View SEC Filing  
11/10/2015Plew Daniel P. VanSVPSell5,123$554.85$2,842,496.55View SEC Filing  
11/9/2015Neil StahlEVPSell42,101$561.45$23,637,606.45View SEC Filing  
11/3/2015P Roy VagelosChairmanSell17,242$580.19$10,003,635.98View SEC Filing  
11/2/2015George YancopoulosinsiderSell43,348$571.61$24,778,150.28View SEC Filing  
10/6/2015SanofiMajor ShareholderBuy80,538$459.71$37,024,123.98View SEC Filing  
9/23/2015SanofiMajor ShareholderBuy147,209$534.67$78,708,236.03View SEC Filing  
9/21/2015Michael S. BrownDirectorSell3,000$551.55$1,654,650.00View SEC Filing  
9/17/2015Charles A. BakerDirectorSell5,000$550.00$2,750,000.00View SEC Filing  
8/14/2015Peter PowchikSVPSell23,485$573.38$13,465,829.30View SEC Filing  
7/15/2015Joseph L GoldsteinDirectorSell2,000$550.00$1,100,000.00View SEC Filing  
6/22/2015Joseph L GoldsteinDirectorSell2,000$526.85$1,053,700.00View SEC Filing  
5/27/2015Robert Alexander IngramDirectorSell1,379$513.39$707,964.81View SEC Filing  
5/26/2015Plew Daniel P VanSVPSell18,370$508.42$9,339,675.40View SEC Filing  
5/22/2015Douglas S MccorkleVPSell13,000$515.60$6,702,800.00View SEC Filing  
5/22/2015Joseph L GoldsteinDirectorSell4,000$514.28$2,057,120.00View SEC Filing  
5/15/2015Michael S BrownDirectorSell5,000$495.00$2,475,000.00View SEC Filing  
3/25/2015Charles A BakerDirectorSell5,000$454.96$2,274,800.00View SEC Filing  
3/24/2015Michael S AbermanSVPSell4,843$478.99$2,319,748.57View SEC Filing  
3/18/2015Michael S AbermanSVPSell3,442$465.00$1,600,530.00View SEC Filing  
3/17/2015Robert J TerifaySVPSell10,993$451.01$4,957,952.93View SEC Filing  
3/16/2015Joseph J LarosaSVPSell18,311$450.00$8,239,950.00View SEC Filing  
2/27/2015Douglas S MccorkleVPSell3,000$416.24$1,248,720.00View SEC Filing  
2/26/2015Marc Tessier-LavigneDirectorSell3,000$421.95$1,265,850.00View SEC Filing  
2/24/2015Robert J TerifaySVPSell11,173$423.67$4,733,664.91View SEC Filing  
2/23/2015Plew Daniel P VanSVPSell9,431$427.82$4,034,770.42View SEC Filing  
2/20/2015Joseph L GoldsteinDirectorSell5,000$423.65$2,118,250.00View SEC Filing  
2/17/2015Michael S AbermanSVPSell3,692$404.46$1,493,266.32View SEC Filing  
1/2/2015Leonard S SchleiferCEOSell1,500$410.58$615,870.00View SEC Filing  
1/2/2015Peter PowchikSVPSell10,822$414.08$4,481,173.76View SEC Filing  
12/24/2014SanofiMajor ShareholderBuy201,459$393.21$79,215,693.39View SEC Filing  
12/16/2014Douglas S MccorkleVPSell8,486$410.15$3,480,532.90View SEC Filing  
11/24/2014Alfred G GilmanDirectorSell40,000$408.44$16,337,600.00View SEC Filing  
11/24/2014Neil StahlSVPSell5,307$412.93$2,191,419.51View SEC Filing  
11/18/2014Robert J TerifaySVPSell22,362$405.79$9,074,275.98View SEC Filing  
11/13/2014Plew Daniel P VanSVPSell8,575$399.34$3,424,340.50View SEC Filing  
11/12/2014Joseph L GoldsteinDirectorSell5,000$398.31$1,991,550.00View SEC Filing  
11/12/2014Leonard S SchleiferCEOSell45,817$400.30$18,340,545.10View SEC Filing  
10/28/2014Leonard S SchleiferCEOSell69,112$404.01$27,921,939.12View SEC Filing  
10/24/2014Michael S BrownDirectorSell5,000$399.00$1,995,000.00View SEC Filing  
10/24/2014Murray A GoldbergSVPSell26,788$400.70$10,733,951.60View SEC Filing  
9/16/2014SanofiMajor ShareholderBuy31,717$349.26$11,077,479.42View SEC Filing  
9/15/2014SanofiMajor ShareholderBuy140,632$345.15$48,539,134.80View SEC Filing  
9/10/2014P Roy VagelosChairmanSell10,328$350.07$3,615,522.96View SEC Filing  
8/27/2014Joseph L GoldsteinDirectorSell2,000$350.31$700,620.00View SEC Filing  
8/19/2014Michael S AbermanVPSell3,611$350.00$1,263,850.00View SEC Filing  
8/18/2014Douglas S MccorkleVPSell5,875$353.00$2,073,875.00View SEC Filing  
8/15/2014Michael S BrownDirectorSell3,000$349.20$1,047,600.00View SEC Filing  
8/14/2014Joseph L GoldsteinDirectorSell2,000$347.65$695,300.00View SEC Filing  
8/13/2014P Roy VagelosChairmanSell8,028$340.01$2,729,600.28View SEC Filing  
8/11/2014Neil StahlSVPSell11,646$339.96$3,959,174.16View SEC Filing  
8/11/2014P Roy VagelosChairmanSell11,972$340.11$4,071,796.92View SEC Filing  
8/8/2014Neil StahlSVPSell2,841$340.60$967,644.60View SEC Filing  
8/7/2014Plew Daniel P VanSVPSell6,806$338.37$2,302,946.22View SEC Filing  
8/6/2014Joseph L GoldsteinDirectorSell2,000$331.20$662,400.00View SEC Filing  
7/15/2014SanofiMajor ShareholderBuy129,100$314.92$40,656,172.00View SEC Filing  
7/14/2014SanofiMajor ShareholderBuy300,000$316.80$95,040,000.00View SEC Filing  
7/10/2014SanofiMajor ShareholderBuy175,000$311.08$54,439,000.00View SEC Filing  
7/9/2014SanofiMajor ShareholderBuy348,000$309.76$107,796,480.00View SEC Filing  
7/7/2014SanofiMajor ShareholderBuy356,700$312.37$111,422,379.00View SEC Filing  
7/2/2014SanofiMajor ShareholderBuy212,400$307.25$65,259,900.00View SEC Filing  
7/1/2014SanofiMajor ShareholderBuy212,400$300.20$63,762,480.00View SEC Filing  
6/30/2014SanofiMajor ShareholderBuy262,400$281.17$73,779,008.00View SEC Filing  
5/23/2014Plew Daniel VanSVPSell5,369$295.93$1,588,848.17View SEC Filing  
5/19/2014Sanofimajor shareholderBuy190,751$300.04$57,232,930.04View SEC Filing  
3/28/2014Sanofimajor shareholderBuy306,945$306.73$94,149,239.85View SEC Filing  
3/27/2014Sanofimajor shareholderBuy306,945$311.01$95,462,964.45View SEC Filing  
3/24/2014Charles BakerDirectorSell15,000$302.67$4,540,050.00View SEC Filing  
3/24/2014Sanofimajor shareholderBuy306,945$307.91$94,511,434.95View SEC Filing  
3/21/2014Sanofimajor shareholderBuy305,115$321.22$98,009,040.30View SEC Filing  
3/20/2014Sanofimajor shareholderBuy67,703$328.33$22,228,925.99View SEC Filing  
3/17/2014Michael BrownDirectorSell2,000$334.29$668,580.00View SEC Filing  
3/17/2014Sanofimajor shareholderBuy115,711$328.46$38,006,435.06View SEC Filing  
3/12/2014Sanofimajor shareholderBuy220,995$334.69$73,964,816.55View SEC Filing  
3/11/2014Sanofimajor shareholderBuy380,532$330.41$125,731,578.12View SEC Filing  
3/7/2014Sanofimajor shareholderBuy150,277$328.72$49,399,055.44View SEC Filing  
3/3/2014Sanofimajor shareholderBuy251,594$338.12$85,068,963.28View SEC Filing  
2/27/2014Michael BrownDirectorSell1,000$335.00$335,000.00View SEC Filing  
2/25/2014Joseph GoldsteinDirectorSell1,000$338.86$338,860.00View SEC Filing  
2/25/2014Murray GoldbergSVPSell11,871$339.55$4,030,798.05View SEC Filing  
2/21/2014Alfred GilmanDirectorSell5,000$340.00$1,700,000.00View SEC Filing  
2/21/2014Murray GoldbergSVPSell21,258$336.51$7,153,529.58View SEC Filing  
2/20/2014Joseph GoldsteinDirectorSell1,000$326.99$326,990.00View SEC Filing  
2/18/2014Michael AbermanVPSell3,648$331.42$1,209,020.16View SEC Filing  
2/18/2014Robert TerifaySVPSell12,865$332.68$4,279,928.20View SEC Filing  
2/13/2014Neil StahlSVPSell22,612$318.82$7,209,157.84View SEC Filing  
2/12/2014George YancopoulosInsiderSell88,987$320.33$28,505,205.71View SEC Filing  
2/12/2014Joseph GoldsteinDirectorSell1,000$320.62$320,620.00View SEC Filing  
2/11/2014Alfred GilmanDirectorSell5,000$320.00$1,600,000.00View SEC Filing  
2/11/2014Douglas MccorkleVPSell5,819$325.00$1,891,175.00View SEC Filing  
2/11/2014P Roy VagelosChairmanSell11,475$325.10$3,730,522.50View SEC Filing  
2/7/2014Sanofimajor shareholderBuy168,511$286.78$48,325,584.58View SEC Filing  
2/5/2014Sanofimajor shareholderBuy397,264$284.12$112,870,647.68View SEC Filing  
2/3/2014Sanofimajor shareholderBuy208,972$283.78$59,302,074.16View SEC Filing  
1/28/2014Sanofimajor shareholderBuy157,920$275.90$43,570,128.00View SEC Filing  
1/14/2014Alfred GilmanDirectorSell5,000$300.00$1,500,000.00View SEC Filing  
1/14/2014Douglas MccorkleVPSell4,000$290.00$1,160,000.00View SEC Filing  
1/2/2014Peter PowchikSVPSell20,668$274.77$5,678,946.36View SEC Filing  
12/20/2013Peter PowchikSVPSell9,133$270.21$2,467,827.93View SEC Filing  
11/26/2013George SingDirectorSell10,000$295.00$2,950,000.00View SEC Filing  
11/6/2013Joseph GoldsteinDirectorSell1,000$300.74$300,740.00View SEC Filing  
9/19/2013Leonard SchleiferCEOSell102,949$302.67$31,159,573.83View SEC Filing  
9/19/2013P Roy VagelosChairmanSell145,356$302.86$44,022,518.16View SEC Filing  
9/18/2013Plew Daniel VanSVPSell23,977$303.17$7,269,107.09View SEC Filing  
9/18/2013William RobertsVPSell15,000$304.00$4,560,000.00View SEC Filing  
9/9/2013Leonard S SchleiferCEOSell5,000$275.47$1,377,350.00View SEC Filing  
8/23/2013Joseph GoldsteinDirectorSell1,000$238.29$238,290.00View SEC Filing  
6/10/2013Charles A BakerDirectorSell15,000$251.84$3,777,600.00View SEC Filing  
5/31/2013Arthur F RyanDirectorSell2,500$249.55$623,875.00View SEC Filing  
5/28/2013Joseph L GoldsteinDirectorSell4,000$252.20$1,008,800.00View SEC Filing  
5/21/2013Murray A GoldbergCFOSell66,835$259.74$17,359,722.90View SEC Filing  
5/17/2013Michael S BrownDirectorSell15,000$275.19$4,127,850.00View SEC Filing  
5/14/2013Michael S AbermanVPSell5,529$279.61$1,545,963.69View SEC Filing  
5/13/2013Neil StahlSVPSell23,038$276.88$6,378,761.44View SEC Filing  
5/10/2013George L SingDirectorSell5,000$270.00$1,350,000.00View SEC Filing  
5/8/2013Robert J TerifaySVPSell8,231$261.23$2,150,184.13View SEC Filing  
5/6/2013P Roy VagelosChairmanSell12,018$263.15$3,162,536.70View SEC Filing  
11/27/2012P Roy VagelosChairmanSell64,753$175.22$11,346,020.66View SEC Filing  
11/26/2012Charles A BakerDirectorSell15,000$173.87$2,608,050.00View SEC Filing  
11/14/2012Michael S BrownDirectorSell7,000$147.03$1,029,210.00View SEC Filing  
11/1/2012Arthur F RyanDirectorSell10,000$145.57$1,455,700.00View SEC Filing  
9/6/2012Charles A BakerDirectorSell15,000$150.00$2,250,000.00View SEC Filing  
8/23/2012George L SingDirectorSell10,000$140.50$1,405,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Regeneron Pharmaceuticals (NASDAQ:REGN)
DateHeadline
News IconRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Price Target At ... - Transcript Daily (NASDAQ:REGN)
transcriptdaily.com - February 20 at 9:13 AM
News IconCan Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Hit 598? - Aiken Advocate (NASDAQ:REGN)
aikenadvocate.com - February 18 at 6:36 PM
News IconRegeneron Pharmaceuticals Inc (REGN) Downgraded to "Neutral" at Goldman Sachs Group, Inc (NASDAQ:REGN)
giftedviz.com - February 17 at 7:58 PM
News IconRegeneron Pharmaceuticals Inc (REGN) Downgraded by Goldman Sachs Group, Inc (NASDAQ:REGN)
eleganthomesinla.com - February 17 at 7:58 PM
News IconImpact of Brokerage Rating on Regeneron Pharmaceuticals, Inc.(REGN) (NASDAQ:REGN)
ibusinesslines.com - February 17 at 7:58 PM
News IconRegeneron Pharmaceuticals Inc (REGN) is Downgraded by Goldman to " Neutral" (NASDAQ:REGN)
nyhetsbanken.info - February 17 at 7:58 PM
4-traders.com logoRegeneron Pharmaceuticals : Appeals Court Grants Stay of Permanent Injunction for Praluent® alirocumab During Appeals Process (NASDAQ:REGN)
www.4-traders.com - February 16 at 7:08 PM
4-traders.com logoRegeneron Pharmaceuticals : Appeals Court Grants Stay of Permanent Injunction for Praluent® alirocumab During Appeals Process (NASDAQ:REGN)
www.4-traders.com - February 16 at 7:08 PM
us.rd.yahoo.com logoREGENERON PHARMACEUTICALS INC Financials (NASDAQ:REGN)
us.rd.yahoo.com - February 16 at 7:08 PM
us.rd.yahoo.com logoREGENERON PHARMACEUTICALS INC Financials (NASDAQ:REGN)
us.rd.yahoo.com - February 16 at 7:08 PM
us.rd.yahoo.com logoRegeneron Pharma downgraded by Goldman (NASDAQ:REGN)
us.rd.yahoo.com - February 16 at 7:08 PM
us.rd.yahoo.com logoRegeneron Pharma downgraded by Goldman (NASDAQ:REGN)
us.rd.yahoo.com - February 16 at 7:08 PM
capitalcube.com logoRegeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : REGN-US : February 14, 2017 (NASDAQ:REGN)
www.capitalcube.com - February 15 at 12:37 AM
capitalcube.com logoETFs with exposure to Regeneron Pharmaceuticals, Inc. : February 14, 2017 (NASDAQ:REGN)
www.capitalcube.com - February 15 at 12:37 AM
4-traders.com logoRegeneron Pharmaceuticals : Announces Upcoming 2017 Investor Conference Presentations (NASDAQ:REGN)
www.4-traders.com - February 14 at 5:24 AM
us.rd.yahoo.com logoRegeneron Announces Upcoming 2017 Investor Conference Presentations (NASDAQ:REGN)
us.rd.yahoo.com - February 14 at 5:24 AM
capitalcube.com logoRegeneron Pharmaceuticals, Inc. :REGN-US: Earnings Analysis: 2016 By the Numbers : February 13, 2017 (NASDAQ:REGN)
us.rd.yahoo.com - February 14 at 5:24 AM
4-traders.com logoRegeneron Pharmaceuticals upgraded by Piper Jaffray Companies to overweight. .. (NASDAQ:REGN)
www.4-traders.com - February 13 at 8:51 AM
cnbc.com logoEarly movers: AAPL, DD, TEVA, QSR, FDC, HAS, JCP & more (NASDAQ:REGN)
www.cnbc.com - February 13 at 8:51 AM
4-traders.com logo02/12 Bamco Inc. NY Sells 63 Shares of Regeneron Pharmaceuticals, Inc. $REGN (NASDAQ:REGN)
www.4-traders.com - February 13 at 12:25 AM
News IconConsensus Price Of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Set At $428.285 - Transcript Daily (NASDAQ:REGN)
transcriptdaily.com - February 12 at 7:23 PM
seekingalpha.com logoPraluent Stay Not Enough To Save Regeneron - Seeking Alpha (NASDAQ:REGN)
seekingalpha.com - February 12 at 7:23 PM
schaeffersresearch.com logoTwitter, Cliffs Natural Resources, Regeneron Pharmaceuticals News Today - Schaeffers Research (blog) (NASDAQ:REGN)
www.schaeffersresearch.com - February 11 at 7:35 PM
seekingalpha.com logoMr. Market Rejects Risky Regeneron: Why Argue? - Seeking Alpha (NASDAQ:REGN)
seekingalpha.com - February 11 at 7:35 PM
News IconForward Earnings Estimate of Regeneron Pharmaceuticals, Inc.(REGN) - Highland Mirror (NASDAQ:REGN)
www.highlandmirror.com - February 11 at 7:35 PM
reuters.com logoBRIEF-Regeneron posts Q4 adj. profit $3.04/shr (NASDAQ:REGN)
www.reuters.com - February 10 at 10:25 PM
News IconForward Earnings Estimate of Regeneron Pharmaceuticals, Inc.(REGN) (NASDAQ:REGN)
xboxonezone.com - February 10 at 10:25 PM
News IconRegeneron Pharmaceuticals, Inc. (REGN) Rating Reiterated by Credit Suisse Group (NASDAQ:REGN)
ekosvoice.com - February 10 at 10:25 PM
us.rd.yahoo.com logo[$$] 12 Stocks to Benefit Most From the House Tax Plan (NASDAQ:REGN)
us.rd.yahoo.com - February 10 at 10:25 PM
capitalcube.com logoRegeneron Pharmaceuticals, Inc. :REGN-US: Earnings Analysis: Q4, 2016 By the Numbers : February 10, 2017 (NASDAQ:REGN)
us.rd.yahoo.com - February 10 at 10:25 PM
News IconRegeneron Pharmaceuticals Inc (REGN) Releases Earnings Results, Misses Expectations By $-0.04 EPS (NASDAQ:REGN)
latribunadecanarias.com - February 10 at 4:09 AM
rttnews.com logoRegeneron Gets Subpoena On Patient Assistance Non-profit (NASDAQ:REGN)
www.rttnews.com - February 9 at 11:07 PM
News IconRegeneron Pharmaceuticals, Inc. Earnings Miss Estimates, But Sees Progress In Key Court Battle (NASDAQ:REGN)
www.talkmarkets.com - February 9 at 11:07 PM
marketexclusive.com logoREGENERON PHARMACEUTICALS, INC. (NASDAQ:REGN) Files An 8-K Results of Operations and Financial Condition (NASDAQ:REGN)
marketexclusive.com - February 9 at 11:07 PM
News IconRegeneron Pharmaceuticals Reports 37% Rise In Q4 Profit (NASDAQ:REGN)
xboxonezone.com - February 9 at 11:07 PM
News IconRegeneron Pharmaceuticals, Inc. (REGN) Releases Earnings Results, Beats Estimates By $0.01 EPS (NASDAQ:REGN)
hoyentv.com - February 9 at 11:07 PM
us.rd.yahoo.com logoRegeneron (REGN) Q4 Earnings Misses Estimates (NASDAQ:REGN)
us.rd.yahoo.com - February 9 at 11:07 PM
us.rd.yahoo.com logoJudge Lifts Ban on Amgen Cholesterol Drug Rival (NASDAQ:REGN)
us.rd.yahoo.com - February 9 at 11:07 PM
us.rd.yahoo.com logoRegeneron (REGN) Misses on Q4 Earnings & Sales, View Bleak (NASDAQ:REGN)
us.rd.yahoo.com - February 9 at 11:07 PM
us.rd.yahoo.com logoRegeneron Pharmaceuticals Inc (REGN) and Sanofi SA (ADR) (SNY) Obtain Suspension of Injunction for Cholesterol Drug Sales (NASDAQ:REGN)
us.rd.yahoo.com - February 9 at 11:07 PM
wsj.com logo[$$] Regeneron Is Primed for a Second Act (NASDAQ:REGN)
us.rd.yahoo.com - February 9 at 11:07 PM
marketwatch.com logoRegeneron says it is being investigated by the US Attorney's Office over patient assistance nonprofit (NASDAQ:REGN)
us.rd.yahoo.com - February 9 at 11:07 PM
finance.yahoo.com logoEdited Transcript of REGN earnings conference call or presentation 9-Feb-17 1:30pm GMT (NASDAQ:REGN)
finance.yahoo.com - February 9 at 11:07 PM
feeds.benzinga.com logoStay Of Court Injunction A Mild Positive For Regeneron (NASDAQ:REGN)
feeds.benzinga.com - February 9 at 12:34 PM
News IconRegeneron, Sanofi win stay of US order blocking cholesterol drug sales (NASDAQ:REGN)
www.channelnewsasia.com - February 9 at 3:50 AM
reuters.com logoBRIEF-Regeneron pharmaceuticals says appeals court grants stay of permanent injunction for praluent (NASDAQ:REGN)
www.reuters.com - February 9 at 3:50 AM
marketwatch.com logoSanofi, Regeneron can sell cholesterol drug again (NASDAQ:REGN)
www.marketwatch.com - February 8 at 10:48 PM
streetinsider.com logoRegeneron (REGN) and Sanofi (SNY) Confirm Stay of Permanent Injunction for Praluent (AMGN) (NASDAQ:REGN)
www.streetinsider.com - February 8 at 10:48 PM
reuters.com logoRegeneron, Sanofi win stay of U.S. order blocking cholesterol drug sales (NASDAQ:REGN)
www.reuters.com - February 8 at 10:48 PM
wsj.com logo[$$] Sanofi Seeks Cure for FDA Concerns at French Factory (NASDAQ:REGN)
us.rd.yahoo.com - February 8 at 10:48 PM

Social

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Where is Regeneron Pharmaceuticals' stock going? Where will Regeneron Pharmaceuticals' stock price be in 2017?

24 brokers have issued 1 year price targets for Regeneron Pharmaceuticals' stock. Their forecasts range from $345.00 to $598.00. On average, they anticipate Regeneron Pharmaceuticals' stock price to reach $449.52 in the next year.

When will Regeneron Pharmaceuticals announce their earnings?

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May, 3rd 2017.

What are analysts saying about Regeneron Pharmaceuticals stock?

Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock:

  • According to Zacks Investment Research, "Regeneron’s fourth-quarter results were disappointing with the company missing on both earnings and revenues estimates. Moreover, the guidance for Eylea was also weak. Regeneron suffered a major blow when the U.S District Court in Delaware granted Amgen request for a permanent injunction prohibiting the sale of PCSK9 inhibitor, Praluent. However, on Feb 8, the United States Court of Appeals for the Federal Circuit stayed the injunction appeal. Hence, Regeneron and Sanofi will continue marketing, selling, and manufacturing Praluent in the U.S. during the appeal process. Although sales of Praluent have failed to impress due to the present payer utilization management restrictions in the U.S. and limited market access in Europe, the drug is still expected to have blockbuster potential. Investors should focus on late stage pipeline catalysts - dupilumab and sarilumab. Shares of the company have also underperformed the industry." (2/15/2017)

  • Cowen and Company analysts commented, "This morning REGN reported Q4 earnings." (2/9/2017)

  • Chardan Capital analysts commented, "We believe the news is an important long-term negative, as REGN (Sell, PT$325) is increasingly exposed to what we expect could be a 2017+ theme in wet AMD of treatment burden reduction." (9/30/2016)

Who owns Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (7.46%), State Street Corp (3.09%), Sands Capital Management LLC (2.19%), Artisan Partners Limited Partnership (1.80%), Loomis Sayles & Co. L P (1.63%) and Polen Capital Management LLC (1.28%). Company insiders that own Regeneron Pharmaceuticals stock include Arthur F Ryan, Charles A Baker, Douglas S Mccorkle, George Yancopoulos, Joseph J Larosa, Joseph L Goldstein, Marc Tessier-Lavigne, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Peter Powchik, Plew Daniel P Van, Robert Alexander Ingram, Robert J Terifay and Sanofi.

Who sold Regeneron Pharmaceuticals stock? Who is selling Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Sands Capital Management LLC, Guggenheim Capital LLC, Pinnacle Associates Ltd., Ithaka Group LLC, Teachers Retirement System of The State of Kentucky, Baillie Gifford & Co. and GSA Capital Partners LLP. Company insiders that have sold Regeneron Pharmaceuticals stock in the last year include Arthur F Ryan, Charles A Baker, Joseph L Goldstein and Plew Daniel P Van.

Who bought Regeneron Pharmaceuticals stock? Who is buying Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, Polen Capital Management LLC, Renaissance Technologies LLC, Federated Investors Inc. PA, Russell Investments Group Ltd., Franklin Resources Inc., DSM Capital Partners LLC and Southpoint Capital Advisors LP.

How do I buy Regeneron Pharmaceuticals stock?

Shares of Regeneron Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Regeneron Pharmaceuticals stock cost?

One share of Regeneron Pharmaceuticals stock can currently be purchased for approximately $371.61.

Regeneron Pharmaceuticals (NASDAQ:REGN) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Earnings History Chart

Earnings by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Dividend History Chart

Dividend Payments by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Last Updated on 2/22/2017 by MarketBeat.com Staff